• Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL
  • Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Drugs with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
  • Immunophenotypic and Quantitative Impacts of Ibrutinib and Chlorambucil on Circulating Immune Cells in CLL
  • Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study
  • Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: The GENUINE Study
  • COSMOS: MOR208 plus Idelalisib or Venetoclax in Relapsed/Refractory CLL or SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor
Chicago, IL—Survival with the use of a tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia (CML) in the chronic phase is comparable among the available drugs, so other variables should come into play when selecting a specific TKI. In some instances, a treatment-free remission is possible, said CML experts at the 2017 ASCO annual meeting.
  • Allogeneic Transplant Leads to Markedly Improved Survival in Older Patients with AML
  • Effect of Cytarabine/Anthracycline/Crenolanib Induction on MRD in Newly Diagnosed AML with FLT3 Mutation
  • Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
  • Improved Survival with Fludarabine and Timed Sequential Busulfan Regimen in Older Patients with AML or MDS
  • Sorafenib plus 5-Azacytidine in Older, Untreated FLT3-ITD–Positive Patients with AML
  • Nivolumab with Azacytidine in Patients with Relapsed AML
San Diego, CA—Combination induction therapy with ibrutinib (Imbruvica) and rituximab (Rituxan) in patients with mantle-cell lymphoma (MCL) led to objective responses in each of the first 50 patients who received this combination in an ongoing, phase 2 clinical trial presented at the 2016 American Society of Hematology meeting.
San Diego, CA—Although tyrosine kinase inhibitors (TKIs) including imatinib (Gleevec), nilotinib (Tasigna), and dasatinib (Sprycel), have dramatically improved outcomes in patients with chronic myeloid leukemia (CML), the costs of these drugs have spiraled out of control, causing some patients to stop treatment or cut their dosage because of financial toxicity. Data presented at the 2016 American Society of Hematology meeting show that it is possible for some patients with CML to reduce their TKI dose by 50% and maintain remission, perhaps even stop treatment altogether once deep and durable remission has been achieved after approximately 5 years of treatment.
San Diego, CA—Induction therapy with a liposomal formulation of cytarabine and daunorubicin CPX-351 (Vyxeos) is superior to cytarabine plus daunorubicin (7+3 regimen) in patients with acute myeloid leukemia (AML), according to a subgroup analysis of a large phase 3 clinical trial that was presented at the 2016 American Society of Hematology (ASH) meeting.
San Diego, CA—Targeting a second-­generation tyrosine kinase inhibitor (TKI) in mutation-specific chronic myeloid leukemia (CML) led to deep and durable responses that were maintained beyond 3 years in some cases, reported Neil Shah, MD, PhD, Department of Medicine/Hematology-Oncology, University of California San Francisco, during a poster presentation at the 2016 American Society of Hematology meeting.
San Diego, CA—Maintenance therapy with lenalidomide (Revlimid) after frontline chemotherapy markedly prolonged progression-free survival (PFS) in patients with high-risk chronic lymphocytic leukemia (CLL), according to interim results from a phase 3 study presented at the 2016 American Society of Hematology meeting.
  • 5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL
  • Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL
  • Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification
  • Reviewing the Demographics and First-Line Treatment Patterns in Patients with CLL
  • Comparing Healthcare Utilization of 2 Drug Regimens in Patients with CLL

A durable complete response was achieved in a high proportion of adults with refractory B-cell malignancies who received CD19+ chimeric antigen receptor (CAR) T-cells made up of a defined 1:1 ratio of CD8+ and CD4+ cells.

Page 1 of 5
Results 1 - 10 of 46
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME